M

PriceMoleculin Biotech

MBRX

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company’s Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Historical stock price chart and annual return over the past years

-100%

5 years

% Total

MBRX
-69%

5 years

Annual Return

MBRX